programas cribado cancer

ACTUALIZACIÓN BIBLIOGRÁFICA

Nota Bibliográfica

Esta Nota es una recopilación de publicaciones (artículos, informes, libros) sobre cribado de cáncer resultado de una revisión no sistemática de la literatura.

Podéis dirigir vuestros comentarios o sugerencias sobre la Nota a:

Josep A Espinás. Pla Director d'Oncología de Catalunya.
Correo electrónico: Esta dirección electrónica esta protegida contra spam bots. Necesita activar JavaScript para visualizarla

Nota bibliográfica cribado c pulmón 2014-02

Kanne JP. Screening for Lung Cancer: What Have We Learned? Am J Roentgenol. 2014;202(3):530–5. Available from: http://dx.doi.org/10.2214/AJR.13.11540. doi: 10.2214/AJR.13.11540.

CONCLUSION. Lung cancer remains the leading cause of cancer-related death in the United States and the world. The National Lung Screening Trial showed a 20% reduction in lung cancer mortality among individuals at high risk undergoing low-dose CT. The findings opened the door for clinical lung cancer screening and publication of lung cancer screening guidelines. However, many questions remain, including whom to screen, how often, and for how long. Furthermore, costs and effects on the health care system remain unclear

 

Nota bibliográfica cribado c pulmón 2014-01

Chiles C. Lung cancer screening with low-dose computed tomography. Radiol Clin North Am. 2014;52(1):27–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24267709. doi: 10.1016/j.rcl.2013.08.006. PMID: 24267709.

Current guidelines endorse low-dose computed tomography (LDCT) screening for smokers and former smokers aged 55 to 74, with at least a 30-pack-year smoking history. Adherence to published algorithms for nodule follow-up is strongly encouraged. Future directions for screening research include risk stratification for selection of the screening population and improvements in the diagnostic follow-up for indeterminate pulmonary nodules. Screening for lung cancer with LDCT has revealed that there are indolent lung cancers that may not be fatal. More research is necessary if the risk-benefit ratio in lung cancer screening is to be maximized.

 

Nota bibliográfica cribado c pulmón 2013-12

Mets OM, Schmidt M, Buckens CF, Gondrie MJ, Isgum I, Oudkerk M, et al. Diagnosis of chronic obstructive pulmonary disease in lung cancer screening Computed Tomography scans: independent contribution of emphysema, air trapping and bronchial wall thickening. Respir Res. 2013;14(1):59. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3673831&tool=pmcentrez&rendertype=abstract. doi: 10.1186/1465-9921-14-59. PMID: 23711184.
CONCLUSION: Quantitatively assessed CT emphysema, air trapping and bronchial wall thickness each contain independent diagnostic information for COPD, and these imaging biomarkers might prove useful in the absence of lung function testing and may influence lung cancer screening strategy. Inspiratory CT biomarkers alone may be sufficient to identify patients with COPD in lung cancer screening setting.
Detterbeck FC, Unger M. Screening for Lung Cancer: Moving Into a New Era. Ann Intern Med. 2013;N/A(N/A):N/A–N/A. Available from: http://dx.doi.org/10.7326/M13-2904.
Patz Jr. EF, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemägi MC, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2013;-. Available from: http://dx.doi.org/10.1001/jamainternmed.2013.12738. doi: 10.1001/jamainternmed.2013.12738. PMID: 24322569.
Conclusions and Relevance More than 18% of all lung cancers detected by LDCT in the NLST seem to be indolent, and overdiagnosis should be considered when describing the risks of LDCT screening for lung cancer.
De Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, et al. Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;N/A(N/A):N/A–N/A. Available from: http://dx.doi.org/10.7326/M13-2316.
Conclusion: Annual CT screening for lung cancer has a favorable benefit-to-harm ratio for individuals ages 55 through 80 years with 30 or more pack-years’ exposure to smoking.Primary Funding Source: National Cancer Institute.
Bach PB. Raising the Bar for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;N/A(N/A):N/A–N/A. Available from: http://dx.doi.org/10.7326/M13-2926.
Moyer VA. Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2013;N/A(N/A):N/A–N/A. Available from: http://dx.doi.org/10.7326/M13-2771.
Recommendation: The USPSTF recommends annual screening for lung cancer with low-dose computed tomography in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. (B recommendation)
Pastorino U, Sverzellati N. Lung cancer: CT screening for lung cancer - do we have an answer? Nat Rev Clin Oncol. 2013;10(12):672–3. Available from: http://dx.doi.org/10.1038/nrclinonc.2013.198. doi: 10.1038/nrclinonc.2013.198.
Midthun DE, Gould MK. Favorable Stage Distribution in the NELSON Trial. Am J Respir Crit Care Med.  2013;187(8):792–3. Available from: http://dx.doi.org/10.1164/rccm.201302-0314ED. doi: 10.1164/rccm.201302-0314E

   

Nota bibliográfica cribado c pulmón 2013-09

McWilliams A, Tammemagi MC, Mayo JR, Roberts H, Liu G, Soghrati K, et al. Probability of Cancer in Pulmonary Nodules Detected on First Screening CT. N Engl J Med. 2013;369(10):910–9.
 Available from: http://dx.doi.org/10.1056/NEJMoa1214726. doi: 10.1056/NEJMoa1214726.

Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, et al. Results of the Two Incidence Screenings in the National Lung Screening Trial. N Engl J Med. 2013;369(10):920–31. Available from: http://dx.doi.org/10.1056/NEJMoa1208962. doi: 10.1056/NEJMoa1208962.

Friedrich MJ. Task force recommends targeted lung cancer screening. JAMA. 2013;310(9):892–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24002258. doi: 10.1001/jama.2013.276646. PMID: 24002258

 

Nota bibliográfica cribado c pulmón 2013-07/08

Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, et al. Targeting of Low-Dose CT Screening According to the Risk of Lung-Cancer Death. N Engl J Med 2013 07/18; 2013/07;369(3):245-254. DOI:10.1056/NEJMoa1301851. Enlace:http://dx.doi.org/10.1056/NEJMoa1301851.

Marshall HM, Bowman RV, Crossin J, Lau MA, Slaughter RE, Passmore LH, et al. Queensland Lung Cancer Screening Study: rationale, design and methods. Intern Med J 2013 Feb;43(2):174-182. DOI:10.1111/j.1445-5994.2012.02789.x; PMID:22471951.

CONCLUSIONS: Studying LDCT screening in the Australian setting will help us understand how differences in populations, background diseases and healthcare structures modulate screening effectiveness. This information, together with results from overseas randomised studies, will inform and facilitate local policymaking.

Field JK, Oudkerk M, Pedersen JH, Duffy SW. Prospects for population screening and diagnosis of lung cancer. The Lancet 2013 8/24–30;382(9893):732-741. DOI:http://dx.doi.org/10.1016/S0140-6736(13)61614-1.

Summary Deaths from lung cancer exceed those from any other type of malignancy, with 1·5 million deaths in 2010. Prevention and smoking cessation are still the main methods to reduce the death toll. The US National Lung Screening Trial, which compared CT screening with chest radiograph, yielded a mortality advantage of 20% to participants in the CT group. International debate is ongoing about whether sufficient evidence exists to implement CT screening programmes. When questions about effectiveness and cost-effectiveness have been answered, which will await publication of the largest European trial, NELSON, and pooled analysis of European CT screening trials, we discuss the main topics that will need consideration. These unresolved issues are risk prediction models to identify patients for CT screening; radiological protocols that use volumetric analysis for indeterminate nodules; options for surgical resection of CT-identified nodules; screening interval; and duration of screening. We suggest that a demonstration project of biennial screening over a 4-year period should be undertaken.

Hew M, Stirlinh RG, Abramson MJ. Should we screen for lung cancer in Australia? (editorial). Med J Aust 2013;199(2):82-83. DOI:10.5694/mja13.10439.
Veronesi G, Maisonneuve P, Bellomi M, Rampinelli C, Durli I, Bertolotti R, et al. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med 2012 Dec 4;157(11):776-784. DOI:10.7326/0003-4819-157-11-201212040-00005; PMID:23208167.

CONCLUSION: Slow-growing or indolent cancer comprised approximately 25% of incident cases, many of which may have been overdiagnosed. To limit overtreatment in these cases, minimally invasive limited resection and nonsurgical treatments should be investigated.

   

Página 3 de 5

balidea
web desarrollada y mantenida por :